Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARS phase 2 study of gaboxadol in adolescents and adults with Angelman syndrome
MOH_2017-05-14_000299Phase 2Completed
- Sponsor
- Ovid Therapeutics
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gaboxadol in Angelman syndrome (AS), sponsored by Ovid Therapeutics. Started Apr 2017; status: completed.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on MOH_2017-05-14_000299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-14_000299.